Oncolytics Biotech (TSX:ONC), (NASDAQ:ONCY) focuses on the development of oncology therapies by leveraging the power of immunotherapy and viral therapy to target cancer cells directly. This pioneering approach seeks to transform cancer treatment by harnessing the body's immune system to fight tumors more effectively. Currently, their flagship project revolves around pelareorep, an intravenously delivered immuno-oncolytic virus showing promise in multiple clinical trials across various cancer types. The objective of Oncolytics Biotech is to continue advancing these studies, aiming to provide new, effective treatment options for patients battling cancer. Their efforts are directed towards achieving significant milestones in cancer therapy, contributing to the broader goal of improving patient outcomes and quality of life.